Inflation Hits Cannabis Industry as Prices Rise

Aug.09.2022
Inflation Hits Cannabis Industry as Prices Rise
Inflation is impacting the cannabis industry, with one in four retailers reporting plans to raise prices by over 10%.

Although inflation has already disrupted many people's plans for summer off-road trips, the impact of rising prices could soon cause real harm to certain individuals.


So far, marijuana and many related products have largely shed the double-digit growth seen in many foods, from chicken to avocados. An analysis firm even reported that prices for marijuana flowers, edibles, and vape products fell by 16.7%, 11.8%, and 12.4%, respectively, between January 2021 and 2022.


Due to a variety of interconnected reasons, such as lack of available materials and supply chain disruptions, the prices of most things have been steadily and rapidly increasing at a rate unseen in 40 years. Even if the prices of main products have not risen, the increase in packaging material costs has had little effect on any industry.


From June 2021 to June 2022, the Consumer Price Index has increased 9.1%. Additionally, according to a recent report from the cannabis industry and accounting firm GreenGrowth CPAs, the cannabis industry may finally be experiencing inflation. With labor and material costs for producing ready-to-eat cannabis products on the rise, one in four cannabis retailers report that they have already increased or plan to increase prices by 10% or more next year.


According to the report, the impact of the COVID-19 pandemic on cannabis businesses has been relatively limited. Based on last year's data, supply chain and recruitment difficulties were reported as issues affecting almost all industries in 2021, in addition to supply challenges being the most common issue currently impacting operators. The survey examined over 700 companies in states where recreational or medical cannabis use is legal, including startups and large multinational operators. While 70% of operators reported they would attempt to absorb rising costs rather than raise prices, 30% plan to proactively increase prices to prevent losses.


The survey found that there were differing opinions among respondents regarding responsibility for rising inflation, with 40% citing policies of the Biden administration and 30% attributing it to lingering impacts of the Trump administration. Other reasons quoted by operators included supply-chain issues, conflicts with countries like Russia and China, and effects of the oil industry's operations. Nationwide numbers are not entirely reflective as marijuana use and production currently remain illegal at a federal level. However, despite price increases, demand for marijuana has remained strong during and after the COVID-19 outbreak. Since the start of quarantine, some online delivery services in California have seen sales increase by 500%.


After two years of crisis and uncertainty following the global pandemic, cannabis financial operators find themselves navigating a range of new, complex situations and business obstacles," the report states. "But it's not all bad news. Many operators have benefited from the surge in demand and are using this new windfall to develop ambitious growth plans.


Statement


This article is compiled from third-party information and is intended for industry communication and learning purposes only.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is only intended for industry communication and research.


Due to limitations in translation proficiency, the translated article may not fully correspond with the original text. Therefore, the original text should be referred to for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong, Macau, Taiwan, and foreign affairs positions and statements.


The copyright of the compiled information belongs to the original media and author, and if there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
mperial Brands’ HY26 results point to a more selective NGP transition. The company is using cash flow from traditional tobacco to fund targeted investments in modern oral nicotine, heated tobacco and reusable vaping systems. Its decision to exit the legacy myblu vaping business in the U.S., while expanding Zone nicotine pouches. In Europe, Imperial’s NGP growth is being driven by a multi-category portfolio including blu, Pulze and Zone/Skruf.
Special Report
May.12
South Korea Moves Against Synthetic Nicotine Regulatory Gap as Three Companies Face Tobacco Business Act Probe
South Korea Moves Against Synthetic Nicotine Regulatory Gap as Three Companies Face Tobacco Business Act Probe
South Korea’s Ministry of Finance and Economy said on May 4 that it requested the Daejeon Metropolitan Police Agency and Gyeonggi Nambu Provincial Police Agency to investigate three sales companies on suspicion of violating the Tobacco Business Act.
May.06 by 2FIRSTS.ai
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands said it will phase out its myblu vaping business in the United States, citing prolonged FDA approval timelines for new vape products. The company said it will instead focus on modern oral nicotine products in the U.S., including the expansion of its Zone brand and new flavors. While overall next-generation product revenue continued to grow, revenue from the category in the Americas declined sharply.
May.12
AIR Shares Drop 18.6% in Nasdaq Debut, Testing Hookah’s Move Toward Public Markets
AIR Shares Drop 18.6% in Nasdaq Debut, Testing Hookah’s Move Toward Public Markets
AIR Global’s Nasdaq debut under ticker AIIR ended with a 18.6% first-day decline, giving the global hookah industry a rare public-market reference point. Beyond one company’s share move, the listing raises a broader question: can a culturally rooted, fragmented and venue-based category evolve into a more scalable and investable consumer sector?
Special Report
May.19
Special Report|Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?
Special Report|Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?
Haypp Group reported a 40% year-on-year increase in nicotine pouch volumes in the first quarter of 2026, with U.S. and U.K. volumes rising 123% and 102%, respectively. Haypp says around 97% of its consumer traffic is organic and that its Media & Insights business provides brand owners with on-site visibility, trial activation and consumer intelligence. For international tobacco companies, Haypp may be both a growth partner for modern oral products and a new source of channel leverage.
Special Report
May.22
 BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention
BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention
British American Tobacco’s London-listed shares rose 13.99% last week, as investors focused on the U.S. Food and Drug Administration’s recent authorization of flavored Glas e-cigarette products, the dismissal of a U.S. sanctions-related criminal case against BAT, and the company’s previously announced share buyback plan and newer nicotine business performance.
BAT
May.18